The European opioid use disorder market will reach USD 131.3 million by 2025 growing at 5.8% CAGR, 2025 to 2035. The primary catalysts for growth are the swiftly escalating rates of opioid addiction, largely attributed to the misuse of prescription medications and other narcotics.
Moreover, various entities-such as governments, healthcare providers and NGOs-are intensifying their efforts to mitigate the opioid crisis; consequently, there is a rise in the adoption of medication-assisted treatment (MAT), which integrates behavioral therapies with FDA-approved medications.
Furthermore, the market is bolstered by a growing availability of naloxone, an opioid antagonist employed in overdose prevention efforts, which is increasingly incorporated into public health initiatives.
Technical advancements (for instance, in digital therapeutics) like mobile applications and telemedicine platforms are enhancing patient monitoring, engagement and treatment adherence. These solutions effectively tackle barriers such as stigma, limited access to in-person care and geographical disparities.
In Europe, strict healthcare regulations coupled with evidence-based practices facilitate the broad adoption of treatment protocols. However, stigma, inadequate funding and regional disparities in treatment access present significant challenges to growth.
| Attributes | Details |
|---|---|
| Estimated Value (2025) | USD 131.3 million |
| Value-based CAGR (2025 to 2035) | 5.8% |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
Increasing Availability of Naloxone
Public health campaigns and regulatory support have expanded the availability of naloxone across Europe. Programs providing naloxone kits to at-risk individuals and their families have become standard practice in many countries.
Growing Adoption of Medication-Assisted Treatment
MAT is the cornerstone of treatment in Europe, combining FDA-approved medications with counseling and behavioral therapies. This holistic approach is gaining traction as it significantly reduces relapse rates and improves patient outcomes.
Rise of Digital Therapeutics
Digital tools, including mobile apps and telemedicine platforms, are improving patient engagement and adherence to treatment plans. These technologies address barriers such as stigma and accessibility, particularly in rural areas.
| Industry | Growth Trends |
|---|---|
| Healthcare Providers | Hospitals and specialized addiction treatment centers are adopting evidence-based practices, including MAT and overdose prevention strategies. |
| Digital Health | Telemedicine platforms and mobile apps for OUD treatment are rapidly expanding, enabling remote monitoring and access to care. |
| Countries | CAGR |
|---|---|
| UK | 4.5% |
| Germany | 4.8% |
| Italy | 3.7% |
| France | 5.2% |
| Spain | 5.1% |
| Rest of Europe | 2.9% |
| Countries | Market Insights |
|---|---|
| UK | The UK leads the European market, driven by strong public health campaigns, widespread MAT adoption, and government-backed naloxone distribution initiatives. Efforts to integrate OUD treatment with mental health services are boosting patient outcomes. |
| Germany | Germany’s market is growing steadily due to its focus on long-acting therapies and digital tools for patient monitoring. The government’s emphasis on decriminalizing addiction and providing MAT in prisons is noteworthy. |
| Italy | Italy’s conservative cultural landscape creates stigma around OUD treatment, but recent government initiatives are expanding MAT programs and naloxone availability in emergency settings. |
| France | France has a high adoption rate of MAT, particularly buprenorphine-based treatments. Public awareness campaigns and NGO participation are driving naloxone access and overdose prevention efforts. |
| Spain | Spain’s market growth is fueled by increased adoption of MAT and naloxone in harm reduction programs. |
| Rest of Europe | Other European countries, including Eastern Europe, face challenges due to stigma, limited funding, and inadequate healthcare infrastructure. However, NGO-led programs are expanding treatment access in underserved areas. |
Europe’s OUD treatment market is moderately consolidated, with established pharmaceutical companies and emerging digital health innovators shaping the competitive landscape.
Analyst Commentary
Global leaders such as Indivior, Pfizer, and Alkermes dominate the European market with a wide portfolio of MAT drugs. Domestic players focus on meeting localized needs, including culturally sensitive care and language-specific digital tools. Non-governmental organizations also play a significant role, particularly in increasing naloxone availability.
| Vendor Tier | Tier 1 |
|---|---|
| Key Vendors | Indivior, Alkermes, Pfizer |
| Market Share (%) | 60% |
| Description | Global leaders offering MAT drugs such as buprenorphine, methadone, and extended-release naltrexone. |
| Vendor Tier | Tier 2 |
|---|---|
| Key Vendors | Camurus, Accord Healthcare, Mundipharma |
| Market Share (%) | 30% |
| Description | Regional players focusing on injectable therapies and combination treatments. |
| Vendor Tier | Tier 3 |
|---|---|
| Key Vendors | Emerging startups and digital health providers |
| Market Share (%) | 10% |
| Description | Innovators providing telehealth platforms and digital therapeutics to improve adherence and access. |
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Rising Prevalence of Opioid Addiction
The misuse of prescription opioids and illicit substances has led to an increasing burden of opioid addiction across Europe, driving demand for effective treatments.
Government Initiatives and Public Awareness
Regulatory policies, funding for addiction treatment programs, and public health campaigns are promoting access to OUD care and destigmatizing addiction.
Technological Advancements in Treatment Delivery
Digital therapeutics, telemedicine platforms, and long-acting medications are improving treatment adherence and expanding access to care in underserved regions
Stigma Associated with OUD Treatment
Stigma surrounding addiction remains a significant barrier to treatment-seeking behavior, particularly in conservative communities.
Limited Access in Rural Areas
Geographical disparities in healthcare infrastructure create challenges in delivering OUD treatment to remote areas.
Funding Constraints
Inadequate funding for addiction treatment programs and limited insurance coverage for MAT medications hinder market growth.
The European opioid use disorder treatment market will reach USD 267.7 million by 2035 driven by MAT, public awareness and digital health. Long acting injectable therapies like extended release naltrexone will be more prominent as they improve adherence and reduce relapse.
Digital therapeutics such as telemedicine platforms and mobile apps will tackle stigma, geographical disparities and limited access to care. Governments and NGOs will be key in increasing naloxone availability, harm reduction and integrating OUD treatment with mental health. By 2035 Europe will be a leader in evidence based OUD treatment - innovation, patient centred care and public health outcomes.
The European opioid use disorder treatment market is a thriving one driven by innovation, government policy and growing awareness. Global players like Indivior and Pfizer have established MAT drug portfolios while regional players focus on long acting therapies and customised solutions.
By 2035 the market will grow through MAT, long acting therapies and digital health. Continued investment in de-stigmatising addiction and widening access to evidence based treatments will be key to sustained growth.
In terms of drug class, the industry is divided into opioid antagonists (naloxone, naltrexone), opioid agonists and partial agonists (methadone, buprenorphine)
In terms of indication, the industry is segregated into pain management, opioid withdrawal/opioid use disorder (Opioid Use Disorder), alcohol de-addiction, depression.
In terms of end user, the industry is divided into hospitals, rehabilitation centers, community health clinics and home-based care.
The market is expected to grow at a 5.7% CAGR from 2025 to 2035.
Major players include Indivior, Alkermes, Camurus, and regional organizations.
Rising opioid addiction prevalence, government support, and advancements in MAT formulations are primary drivers.
Stigma, high costs of advanced therapies, and barriers to Indigenous access are significant challenges.
Explore Therapy Area Insights
View Reports
Europe Opioid Use Disorder Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
